Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.35 USDC | 0x50ab...12fc |
| solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp | exact | 0.35 tokens | 985iFj...5KX1 |